Clinical trialObsUnknown
Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma
Exploring the Application of 3D Bioprinting Technology in Constructing Preclinical Models of Pancreatic Cancer for Drug Sensitivity Testing and Its Significance in Personalized Treatment
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 1 December 2022
- Expected end
- 30 September 2024
- Enrollment
- 30 participants
- Sites
- 2
- Primary outcomes
- Correlation of Drug Sensitivity in In Vitro Tumor Models with Clinical Response in Patients
- Sponsor
- Other
- Results posted
- No
- Last update
- 21 July 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundOrganoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-20-4116↗
- BackgroundThree-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine. DOI 10.1016/j.biomaterials.2020.120416↗
- BackgroundApplication of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research. DOI 10.3389/fonc.2020.00878↗
- BackgroundOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-18-0349↗
- BackgroundOrganoid models of human and mouse ductal pancreatic cancer. DOI 10.1016/j.cell.2014.12.021↗